Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, announced today the appointment of Argyrios Theofilopoulos, MD of The Scripps Research Institute to its scientific advisory board.
Batu Biologics, an immuno-oncology company, has successfully completed its $1 million seed round of funding, bringing the company one step closer in its efforts to battle lung cancer, the leading cancer killer in the United States. Batu leveraged primarily private and angel funding to attain this fundraising goal.
Batu Biologics has raised $1 million to develop its lung cancer immune therapy, the two-year-old San Diego company said Wednesday.
Batu Biologics announced the issuance of United States patent # 8,999,349 covering composition of matter claims for its ImmXcyteTM immune-oncology peptide technology.